Phaseline

Companies › Shenzhen Kangzhe Biotechnology

Shenzhen Kangzhe Biotechnology: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 1 Phase 2, 1 Phase 1; Oncology, Genitourinary; next expected readout Nov 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
CMS-D002 Capsules–Phase 2Uterine Fibroids With MenorrhagiaJan 2027
CMS-D017–Phase 1Paroxysmal Nocturnal Hemoglobinuria, PNHNov 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07462780CMS-D017Phase 1Paroxysmal Nocturnal Hemoglobinuria, PNHGenitourinaryNov 2026
NCT07402369CMS-D002 CapsulesPhase 2Uterine Fibroids With MenorrhagiaOncologyJan 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Biocity Biopharmaceutics Henan Genuine Biotech Everest Medicines (China) BioRay Pharmaceutical Kind Pharmaceuticals

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.